198 related articles for article (PubMed ID: 37230294)
1. Immune checkpoint-targeted drug conjugates: A promising tool for remodeling tumor immune microenvironment.
Choi J; Jang H; Choi J; Choi Y; Yang Y; Shim MK; Kim SH
J Control Release; 2023 Jul; 359():85-96. PubMed ID: 37230294
[TBL] [Abstract][Full Text] [Related]
2. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
[TBL] [Abstract][Full Text] [Related]
3. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery.
Kyu Shim M; Yang S; Sun IC; Kim K
Adv Drug Deliv Rev; 2022 Apr; 183():114177. PubMed ID: 35245568
[TBL] [Abstract][Full Text] [Related]
4. Boosting Checkpoint Immunotherapy with Biomaterials.
Liu L; Pan Y; Zhao C; Huang P; Chen X; Rao L
ACS Nano; 2023 Feb; 17(4):3225-3258. PubMed ID: 36746639
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
6. Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology.
Liu Z; Xiang Y; Zheng Y; Kang X
Front Immunol; 2022; 13():1027124. PubMed ID: 36341334
[TBL] [Abstract][Full Text] [Related]
7. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
9. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
10. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
11. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.
Nicolò E; Giugliano F; Ascione L; Tarantino P; Corti C; Tolaney SM; Cristofanilli M; Curigliano G
Cancer Treat Rev; 2022 May; 106():102395. PubMed ID: 35468539
[TBL] [Abstract][Full Text] [Related]
12. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber HP; Sapra P; Loganzo F; May C
Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
[TBL] [Abstract][Full Text] [Related]
13. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy.
Shim MK; Song SK; Jeon SI; Hwang KY; Kim K
Expert Opin Drug Deliv; 2022 Jun; 19(6):641-652. PubMed ID: 35603410
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
15. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
Zhou L; Zhang P; Wang H; Wang D; Li Y
Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
[TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
17. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
18. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
19. Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy.
Shang Q; Dong Y; Su Y; Leslie F; Sun M; Wang F
Adv Drug Deliv Rev; 2022 Jun; 185():114308. PubMed ID: 35472398
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy.
Zhou X; Chen X; Han L; Liu H
Clin Sci (Lond); 2022 May; 136(10):771-785. PubMed ID: 35621125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
